News

Pharmabiz5d
Palvella Therapeutics’ drug candidate QTORIN rapamycin receives US patent
Palvella Therapeutics’ drug candidate QTORIN rapamycin receives US patent: Wayne, Pennsylvania Saturday, June 21, 2025, 13:00 Hrs [IST] Palvella Therapeutics Inc, a clinical-sta ...
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 ...
Nasdaq8d
Palvella Therapeutics Secures Patent for QTORIN™ Rapamycin, Strengthening Intellectual Property Strategy Through 2038 - Nasdaq
Potential Positives. Palvella has secured a new U.S. patent (No. 12,329,748) for QTORIN™ rapamycin, enhancing its intellectual property portfolio and reinforcing its exclusivity strategy.
India TV5d
Understanding Metastatic Renal Cell Carcinoma: Doctor explains how cancer spreads and emerging treatment options - India TV News
A doctor breaks down metastatic renal cell carcinoma, explaining how the cancer spreads and discussing emerging treatment options, providing valuable insights for patients and caregivers.
Yahoo Finance8d
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - Yahoo Finance Canada
New intellectual property builds on Palvella’s multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella ...
manilatimes8d
Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1-20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors - The Manila Times
New intellectual property builds on Palvella's multi-layered exclusivity strategy. Patent term expected through at least 2038. WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella ...